Overexpression of somatostatin receptors has been demonstrated in various brain tumours such as meningiomas or glia-derived tumours. This evidence, following the clinical experience on neuroendocrine tumours, suggests that somatostatin analogues may also be of value for the imaging and treatment of the above-mentioned brain neoplasms.
High Grade Glioma Anaplastic Astrocytoma Peptide Receptor Radionuclide Therapy Teaching Point Surgical Radicalization
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Bartolomei M, Bodei L, De Cicco C, et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407–16.PubMedCrossRefGoogle Scholar
Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging. 2002;29:486–93.PubMedCrossRefGoogle Scholar
Reardon DA, Rich JN, Friedman HS, et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006;24:1253–65. Review.PubMedCrossRefGoogle Scholar
Zalutsky MR. Current status of therapy of solid tumors: brain tumour therapy. J Nucl Med. 2005;46:151S–6. Review.PubMedGoogle Scholar
Zoller F, Eisenhut M, Haberkorn U, et al. Endoradiotherapy in cancer treatment – basic concepts and future trends. Eur J Pharmacol. 2009;625:55–62. Review.PubMedCrossRefGoogle Scholar